An Open-Label Study to Characterize the Safety and Response Rate of MabThera (Rituximab) Plus Chlorambucil in Previously Untreated Patients With CD20-Positive B-Cell Chronic Lymphocytic Leukemia
Phase of Trial: Phase II
Latest Information Update: 12 Apr 2016
At a glance
- Drugs Chlorambucil (Primary) ; Rituximab (Primary)
- Indications Chronic lymphocytic leukaemia
- Focus Adverse reactions
- Sponsors Roche
- 19 Sep 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 18 Apr 2011 Planned End Date changed from 1 Oct 2010 to 1 Jun 2012 as reported by ClinicalTrials.gov.
- 15 Feb 2011 Planned end date changed from 1 Dec 2012 to 1 Oct 2010 as reported by ClinicalTrials.gov.